Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial

Zeng, Ming; Xuhu, Mao; Li, Jingxin; Tong, Wende; Wang, Bin; Zhang, Yiju; Guo, Gang; Zhao, Zhiling; Li, Liang; De-lin, WU; Lu, Dongshui; Tan, Zhongming; Liang, Haoyu; Wu, Chao; Li, Da-Han; Luo, Ping; Zeng, Hao; Zhang, Weijun; Zhang, Jinyu; Guo, Botao; Zhu, Fengcai; Zou, Quanming

doi:10.1016/s0140-6736(15)60310-5

Cited by 220 publications

(140 citation statements)

References 25 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…In the context of H. pylori infection, vaccination is not universally available and the efficacy is limited, although a promising field trial in China has recently been reported. (46) In the primary care setting, one can adopt a stepwise approach to the management of H. pylori-associated dyspepsia (Fig. 1).…”

Section: Resultsmentioning

confidence: 99%

The diagnosis and management of H. pylori infection in Singapore

Chew

Lye²,

Ang

2017

smedj

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

The diagnosis and management of H. pylori infection in Singapore

Chew

Lye²,

Ang

2017

smedj

View full text Add to dashboard Cite

“…A successful H. pylori vaccine field trial from China351 has recently been reported. This is a promise for the future and demands increased efforts for further development of a vaccine.…”

Section: Working Group 4: Prevention/public Healthmentioning

confidence: 99%

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

Malfertheiner

Mégraud

O’Moráin

et al. 2016

Gut

2,331

2,886

View full text Add to dashboard Cite

“…A suitable vaccine is yet to be developed. A Chinese prospective, double-blind, placebo-controlled phase III study in children aged 6-15 years demonstrated a preventive effect in 70.8% by an oral recombinant vaccine [124]. These data remains to be confirmed and further discussion is warranted if H. pylori should be eradicated at such an early age.…”

Section: H Pylori Eradicationmentioning

confidence: 99%

The Rationale and Efficacy of Primary and Secondary Prevention in Adenocarcinomas of the Upper Gastrointestinal Tract

Bornschein

Bird‐Lieberman

Malfertheiner

2019

Dig Dis

View full text Add to dashboard Cite

While the primary risk factor for oesophageal adenocarcinoma (OAC) and its precursor lesion Barrett’s oesophagus (BO) is gastro-oesophageal reflux, the infection with Helicobacter pylori (H. pylori) is the dominant risk factor for gastric cancer. Reduction of reflux by dietary measures and proton pump inhibitors has some merits in OAC prevention, and the chemopreventive effect of Aspirin and statins is being widely investigated; however, improved outcome in OAC occurs primarily as the result of secondary prevention. Early detection of neoplastic lesions in Barrett’s metaplasia can be achieved by surveillance endoscopies. Novel endoscopic imaging modalities carry similar importance as the endoscopic treatment techniques as without detection of early lesions, therapy cannot be applied. Minimally invasive approaches are currently being investigated to identify patients with BO who are at particular risk of neoplastic progression. While dietary factors also play an important role in the prevention of gastric cancer and chemoprevention seems to be promising, the most beneficial effect has been shown for the eradication of H. pylori infection, which results in at least a one third reduction of gastric cancer risk. This effect can be further improved if the eradication takes place prior to the development of pre-neoplastic gastric conditions such as mucosal atrophy or intestinal metaplasia (IM). The definition of the “point of no return”, after which eradication is less effective, is of high importance, although H. pylori eradication can still be beneficial even at more advance stages of mucosal changes. For this reason, patients with advanced atrophy and IM should undergo endoscopic surveillance in the same way as patients with BO. There is also need for development of non-invasive tests to identify patients at high risk of progression to gastric cancer to improve outcome of these surveillance approaches.

show abstract

Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial

Cited by 220 publications

References 25 publications

The diagnosis and management of H. pylori infection in Singapore

The diagnosis and management of H. pylori infection in Singapore

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

The Rationale and Efficacy of Primary and Secondary Prevention in Adenocarcinomas of the Upper Gastrointestinal Tract

Contact Info

Product

Resources

About